Literature DB >> 29353981

Retrospective analysis of interventional treatment of hepatic metastasis from gastroenteropancreatic neuroendocrine tumors.

Peng Liu1, Xu Zhu1, Jie Li2, Ming Lu2, Jiahua Leng3, Ying Li4, Jiangyuan Yu5.   

Abstract

OBJECTIVE: To analyze the angiography appearance of liver metastases from gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and evaluate the clinical efficacy and prognostic factors of interventional treatment for hepatic metastases.
METHODS: Fifty GEP-NETs patients with hepatic metastases were treated from January 2012 to December 2016, and received transarterial embolization (TAE) in the hepatic tumor or hepatic arterial infusion chemotherapy (HAIC). All patients received 179 times of the intervention therapy in total.
RESULTS: Blood supplies were identified in the 50 cases with angiography, which showed that 35 cases had abundant vessels, while 15 cases had poor blood supply. Twenty-two cases were found either collateral blood supply, or portal vein invasion or arterial-portal vein fistula. The best curative efficacy was complete remission (CR) in 4 cases, partial remission (PR) in 28 cases and stable disease (SD) in 18 cases during the process of treatment. The angiography (P=0.047) and the frequency of intervention (P=0.037) showed significantly statistical difference with Kaplan-Meier analysis. The Cox analysis showed that more than 3 times of interventional therapy was an independent prognostic factor.
CONCLUSIONS: Interventional treatment is safe and effective for GEP-NETs, and is beneficial to patients with main hepatic metastases after endocrine therapy.

Entities:  

Keywords:  Gastroenteropancreatic neuroendocrine tumors; angiography; hepatic metastasis; interventional treatment; retrospective analysis

Year:  2017        PMID: 29353981      PMCID: PMC5758730          DOI: 10.21147/j.issn.1000-9604.2017.06.13

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  21 in total

1.  Hepatic resection for colorectal metastasis with macroscopic tumor thrombus in the portal vein.

Authors:  Keiichiro Tada; Norihiro Kokudo; Makoto Seki; Masashi Ueno; Kaoru Azekura; Hirotoshi Ohta; Toshiharu Yamaguchi; Toshiki Matusbara; Takashi Takahashi; Toshifusa Nakajima; Akio Yanagisawa; Tetsuichiro Muto
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

2.  Neuroendocrine liver metastases: Vascular patterns on triple-phase MDCT are indicative of primary tumour location.

Authors:  Maxime Ronot; Francesco Cuccioli; Marco Dioguardi Burgio; Marie-Pierre Vullierme; Olivia Hentic; Philippe Ruszniewski; Gaspard d'Assignies; Valérie Vilgrain
Journal:  Eur J Radiol       Date:  2017-02-09       Impact factor: 3.528

Review 3.  GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs.

Authors:  Thierry de Baere; Frederic Deschamps; Lambros Tselikas; Michel Ducreux; David Planchard; Ernesto Pearson; Amandine Berdelou; Sophie Leboulleux; Dominique Elias; Eric Baudin
Journal:  Eur J Endocrinol       Date:  2014-11-10       Impact factor: 6.664

Review 4.  Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases.

Authors:  Sanjay Gupta
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

Review 5.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

6.  Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.

Authors:  Tetsuhide Ito; Hironobu Sasano; Masao Tanaka; R Yoshiyuki Osamura; Iwao Sasaki; Wataru Kimura; Koji Takano; Takao Obara; Miyuki Ishibashi; Kazuwa Nakao; Ryuichiro Doi; Akira Shimatsu; Toshirou Nishida; Izumi Komoto; Yukio Hirata; Kazuhiko Nakamura; Hisato Igarashi; Robert T Jensen; Bertram Wiedenmann; Masayuki Imamura
Journal:  J Gastroenterol       Date:  2010-02       Impact factor: 7.527

7.  "Cherry picking", a multiple non-anatomic liver resection technique, as a promising option for diffuse liver metastases in patients with neuroendocrine tumours.

Authors:  Markus Krausch; Andreas Raffel; Martin Anlauf; Matthias Schott; Nadja Lehwald; Andreas Krieg; Stefan Andreas Topp; Kenko Cupisti; Wolfram Trudo Knoefel
Journal:  World J Surg       Date:  2014-02       Impact factor: 3.352

8.  The clinicopathological significance of angiogenesis in hindgut neuroendocrine tumors obtained via an endoscopic procedure.

Authors:  Yoichiro Okubo; Osamu Motohashi; Norisuke Nakayama; Ken Nishimura; Rika Kasajima; Yohei Miyagi; Manabu Shiozawa; Emi Yoshioka; Masaki Suzuki; Kota Washimi; Kae Kawachi; Madoka Nito; Yoichi Kameda; Tomoyuki Yokose
Journal:  Diagn Pathol       Date:  2016-11-08       Impact factor: 2.644

9.  Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification.

Authors:  Deepak Kalyansingh Burad; Thomas Alex Kodiatte; Sayd Mohamed Rajeeb; Ashish Goel; Chundamannil Eapen Eapen; Banumathi Ramakrishna
Journal:  World J Gastroenterol       Date:  2016-10-28       Impact factor: 5.742

10.  Prognostic factors for transarterial chemoembolization combined with sustained oxaliplatin-based hepatic arterial infusion chemotherapy of colorectal cancer liver metastasis.

Authors:  Hangyu Zhang; Jianhai Guo; Song Gao; Pengjun Zhang; Hui Chen; Xiaodong Wang; Xiaoting Li; Xu Zhu
Journal:  Chin J Cancer Res       Date:  2017-02       Impact factor: 5.087

View more
  1 in total

1.  Utility of CT in differentiating liver metastases of well-differentiated gastroenteropancreatic neuroendocrine neoplasms from poorly-differentiated neuroendocrine neoplasms.

Authors:  Yong Cui; Xiaoting Li; Shunyu Gao; Zhongwu Li; Yanling Li; Ming Lu; Yingshi Sun
Journal:  Chin J Cancer Res       Date:  2018-02       Impact factor: 5.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.